Company News
Arrowhead Reports 80% TG Cut Phase 3
Arrowhead presented Phase 3 SHASTA-3 and SHASTA-4 results showing 79% and 81% triglyceride reductions versus placebo at 12 months.
Over 90% of treated patients achieved TG <500 mg/dL and more than hal
